Protia Inc. (303360.KQ) stock: key figures, P/E, revenue and dividend

Health Care · South Korea

Price
3,595.00 KRW
Market cap
69.44 bn KRW
P/E (2025)
15.53
P/S (2025)
4.59
Dividend yield
0.00 %
Net margin
29.57 %
Return on equity (ROE)
14.57 %
Return on assets (ROA)
13.54 %

Protia Inc. financials

Fiscal year20242025
Revenue10.51 bn KRW15.12 bn KRW
Gross profit6.27 bn KRW9.30 bn KRW
Operating income1.50 bn KRW3.72 bn KRW
EBIT2.34 bn KRW4.23 bn KRW
Net income2.44 bn KRW4.47 bn KRW
Diluted EPS – continuing operations189.65 KRW347.23 KRW

Full history since 2022, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Protia Inc.

Protia Inc. manufactures and sells in vitro diagnostic medical devices in South Korea. It offers allergy, animal diagnosis, autoimmune, antibiotic susceptibility, POCT, cancer, and related instrument products, as well as protein analysis, LC-MS/MS, characterization analysis, and custom protein services. The company was formerly known as ProteomeTech Inc. and changed its name to Protia Inc. in November 2023. Protia Inc. was founded in 2000 and is headquartered in Seoul, South Korea.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.